基于青蒿素的联合疗法治疗疟疾的依从性:证据的系统评价
Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence.
作者信息
Banek Kristin, Lalani Mirza, Staedke Sarah G, Chandramohan Daniel
机构信息
Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK.
出版信息
Malar J. 2014 Jan 6;13:7. doi: 10.1186/1475-2875-13-7.
BACKGROUND
Increasing access to and targeting of artemisinin-based combination therapy (ACT) is a key component of malaria control programmes. To maximize efficacy of ACT and ensure adequate treatment outcomes, patient and caregiver adherence to treatment guidelines is essential. This review summarizes the current evidence base on ACT adherence, including definitions, measurement methods, and associated factors.
METHODS
A systematic search of the published literature was undertaken in November 2012 and updated in April 2013. Bibliographies of manuscripts were also searched and additional references identified. Studies were included if they involved at least one form of ACT and reported an adherence measurement.
RESULTS
The search yielded 1,412 records, 37 of which were found to measure adherence to ACT. Methods to measure adherence focused on self-report, pill counts and bioassays with varying definitions for adherence. Most studies only reported whether medication regimens were completed, but did not assess how the treatment was taken by the patient (i.e. timing, frequency and dose). Adherence data were available for four different ACT formulations: artemether-lumefantrine (AL) (range 39-100%), amodiaquine plus artesunate (AQ + AS) (range 48-94%), artesunate plus sulphadoxine-pyrimethamine (AS + SP) (range 39-75%) and artesunate plus mefloquine (AS + MQ) (range 77-95%). Association between demographic factors, such as age, gender, education and socio-economic status and adherence to ACT regimens was not consistent. Some evidence of positive association between adherence and patient age, caregiver education levels, drug preferences, health worker instructions, patient/caregiver knowledge and drug packaging were also observed.
CONCLUSIONS
This review highlights the weak evidence base on ACT adherence. Results suggest that ACT adherence levels varied substantially between study populations, but comparison between studies was challenging due to differences in study design, definitions, and methods used to measure adherence. Standardising methodologies for both self-report and bioassays used for evaluating adherence of different formulations across diverse contexts would improve the evidence base on ACT adherence and effectiveness; namely, specific and measurable definitions for adherence are needed for both methodologies. Additionally, further studies of the individual factors and barriers associated with non-adherence to ACT are needed in order to make informed policy choices and to improve the delivery of effective malaria treatment.
背景
增加青蒿素联合疗法(ACT)的可及性并精准靶向治疗是疟疾控制项目的关键组成部分。为使ACT疗效最大化并确保获得充分的治疗效果,患者及照料者遵循治疗指南至关重要。本综述总结了目前关于ACT依从性的证据基础,包括定义、测量方法及相关因素。
方法
2012年11月对已发表文献进行了系统检索,并于2013年4月更新。还检索了手稿的参考文献并确定了其他参考文献。若研究涉及至少一种ACT形式并报告了依从性测量结果,则纳入该研究。
结果
检索共获得1412条记录,其中37条记录用于测量对ACT的依从性。测量依从性的方法主要集中在自我报告、清点药片和生物测定,对依从性的定义各不相同。大多数研究仅报告了药物治疗方案是否完成,但未评估患者的服药方式(即时间、频率和剂量)。有四种不同ACT制剂的依从性数据:蒿甲醚-本芴醇(AL)(范围为39%-100%)、阿莫地喹加青蒿琥酯(AQ + AS)(范围为48%-94%)、青蒿琥酯加磺胺多辛-乙胺嘧啶(AS + SP)(范围为39%-75%)和青蒿琥酯加甲氟喹(AS + MQ)(范围为77%-95%)。年龄、性别、教育程度和社会经济地位等人口统计学因素与ACT治疗方案依从性之间的关联并不一致。也观察到一些依从性与患者年龄、照料者教育水平、药物偏好、卫生工作者指导、患者/照料者知识及药物包装之间呈正相关的证据。
结论
本综述突出了ACT依从性方面证据不足的问题。结果表明,不同研究人群中ACT的依从水平差异很大,但由于研究设计、定义及测量依从性所用方法的不同,各研究之间的比较具有挑战性。在不同背景下,对用于评估不同制剂依从性的自我报告和生物测定方法进行标准化,将改善ACT依从性和有效性方面的证据基础;也就是说,两种方法都需要有具体且可衡量的依从性定义。此外,还需要进一步研究与ACT不依从相关的个体因素和障碍,以便做出明智的政策选择并改善有效的疟疾治疗服务。